Invest in Sensore

Sensore: a paradigm shift from reactive to proactive care, revolutionising the £3.7bn pressure ulcer prevention market.

A patented medical device platform designed to reduce one of healthcare’s most costly and preventable conditions. Funded to UKCA certification by Jan 2027, with 50+ paid device pilots booked & ready to scale.

Raising £1.1m (EIS Approved) to scale-up manufacture, launch Sensore S1 in early 2027 and develop Sensore M1 for launch in late 2027.

Sensore: a paradigm shift from reactive to proactive care, revolutionising the £3.7bn pressure ulcer prevention market.

Raising £1.1m (EIS Approved) to scale-up manufacture, launch Sensore S1 in early 2027 and develop Sensore M1 for launch in late 2027.

Where Sensore stands today.

paid device pilots

due Jan 2027

seed raise

committed

Advance Assurance

Route to UKCA Certification Fully Funded
In the last 3 months we have secured £360k in non-dilutive grants,
funding our pathway to UKCA marking expected in January 2027.

Seed Round focused on commercialisation & scale-up

UKCA Certification Fully Funded
In the last 3 months we have secured £360k in non-dilutive grants, funding our pathway to UKCA marking expected in January 2027.

Seed Round focused on commercialisation & scale-up

Seed Milestones

Why Invest Now?

Sensore has validated the problem, technology and early market demand, and is now capitalising on regulatory and market tailwinds to reach commercial scale.

Execution Phase

Core technology is patented and validated, deployed in operational care settings and integrating into real workflows.

This raise funds execution and scale, not product proof.

Persistent, High-Cost Problem

Commercial Validation

Defined Regulatory Pathway

Near-Term Value Inflection

Timing Is Right

View Pitch Deck

Why Invest Now?

Sensore has validated the problem, technology and early market demand, and is now capitalising on regulatory and market tailwinds to reach commercial scale.

Execution Phase

Core technology is patented and validated, deployed in operational care settings and integrating into real workflows.

This raise funds execution and scale, not product proof.

Persistent, High-Cost Problem

Commercial Validation

Defined Regulatory Pathway

Near-Term Value Inflection

Timing Is Right

View Pitch Deck

supported by

Start the conversation.

We are engaging with aligned EIS investors to anchor our seed round, and welcome direct conversations and warm introductions. Our CEO will be in touch shortly.

From reactive to proactive care.

A patented medical device platform designed to reduce one of healthcare’s most costly and preventable conditions, now in paid pilots with UK care providers, addressing the £3.7bn pressure ulcer prevention market.